Physician profile
Eric A Espinosa
NPI 1265405914
$29,107.72
in general payments reported to CMS, 2019-2025
37 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $422 · 2021: $670 · 2022: $647 · 2023: $2,642 · 2024: $11K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $6,719 · Travel and Lodging: $2,560 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,325.00 |
| Food and Beverage | $6,719.26 |
| Travel and Lodging | $2,559.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bluewind Medical | $15,686.38 | 2024-2025 | Revi |
| Medtronic, INC. | $5,086.92 | 2021-2025 | Interstim, Altaviva |
| Teleflex LLC | $1,658.88 | 2021-2025 | Urolift, Barrigel |
| Dendreon Pharmaceuticals LLC | $1,208.82 | 2023-2025 | Provenge |
| Procept Biorobotics Corporation | $1,207.08 | 2019-2025 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $650.12 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Endo USA, INC. | $590.87 | 2024-2025 | Xiaflex |
| Sumitomo Pharma America, INC. | $428.55 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $337.94 | 2019-2025 | Xtandi, Myrbetriq |
| Axonics, INC. | $307.44 | 2023-2024 | Axonics |
| Urogen Pharma, INC. | $215.24 | 2023-2025 | Jelmyto |
| Dornier Medtech America, INC | $208.44 | 2022 | |
| Neotract INC. | $159.58 | 2019-2020 | |
| Calyxo, INC. | $147.61 | 2024-2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $147.02 | 2019-2025 | Erleada, Balversa, Akeega |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $143.53 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $123.29 | 2022-2025 | |
| Olympus America INC. | $116.20 | 2025 | Itind System |
| Endo Pharmaceuticals INC. | $96.29 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.38 | 2021-2025 | |
| Pfizer INC. | $73.62 | 2019-2025 | |
| Valencia Technologies Corporation | $45.39 | 2025 | Ecoin Device Kit |
| Ge Healthcare | $44.18 | 2025 | |
| Antares Pharma, INC. | $42.77 | 2021-2025 | Xyosted |
| Civco Medical Instruments | $38.55 | 2025 | |
| Progenics Pharmaceuticals, INC. | $38.21 | 2023-2024 | Pylarify |
| Agiliti Surgical, INC. | $32.68 | 2021 | |
| Verity Pharmaceuticals INC. | $28.74 | 2025 | Trelstar |
| Baudax Bio INC. | $28.54 | 2021 | |
| Allergan, INC. | $28.07 | 2021-2022 | |
| Telix Pharmaceuticals | $26.67 | 2024 | Illuccix |
| Blue Earth Diagnostics | $21.91 | 2021 | |
| Tolmar, INC. | $17.49 | 2024 | |
| Urovant Sciences INC | $16.13 | 2022 | |
| Medtronic USA, INC. | $14.79 | 2019 | |
| Halozyme INC | $14.40 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$739.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.